Theraclone Sciences competitors

Theraclone Sciences's competitors include Nemus Bioscience, Keryx Biopharmaceuticals, Reneuron Group and Oxford Nanopore Technologies
Add company...
Theraclone Sciences
A privately-held biotechnology company focused on developing novel tumor- specific therapeutic antibodies for the treatment of cancer and infectious disease.
Nemus Bioscience
Nemus Bioscience Inc. is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids.
Keryx Biopharmaceuticals
Keryx Biopharmaceuticals is a biopharmaceutical company focused on the development of products for the treatment of renal diseases.
Reneuron Group
ReNeuron Group engages in R&D and the commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications.
Oxford Nanopore Technologies
Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA and proteins.
Founding Date
Founding Date
2004
Founding Date
2012
Founding Date
1998
Founding Date
1997
Founding Date
2005
Type
Type
Private
Type
Public
Type
Public
Type
Public
Type
Private
Tags
Locations
Locations
Seattle, US HQ
Locations
Costa Mesa, US HQ
Locations
New York, US HQ
Boston, US
Locations
Surrey Research Park, GB HQ
Locations
Oxford, GB HQ
Employees
Employees
820% decrease
Employees
3
Employees
193
Employees
5320% increase
Employees
3101% increase
Valuation ($)
Valuation ($)
N/A
Valuation ($)
4.3 m
Valuation ($)
374.6 m
Valuation ($)
73.5 m
Valuation ($)
1.6 b
Facebook likes
Facebook likes
N/A
Facebook likes
167
Facebook likes
N/A
Facebook likes
N/A
Facebook likes
1.6 k
Twitter followers
Twitter followers
N/A
Twitter followers
706
Twitter followers
391
Twitter followers
N/A
Twitter followers
22.7 k

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$60.6m (FY, 2017)
Revenue (est.)
£46k (FY, 2017)
Revenue (est.)
£13.8m (FY, 2017)
Cost of goods
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$22m (FY, 2017)
Cost of goods
N/A
Cost of goods
£7.1m (FY, 2017)
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
$38.7m (FY, 2017)
Gross profit
N/A
Gross profit
£6.7m (FY, 2017)
Net income
Net income
N/A
Net income
($3.1m) (FY, 2017)
Net income
($163.4m) (FY, 2017)
Net income
(£15.6m) (FY, 2017)
Net income
(£56.5m) (FY, 2017)

Funding

Latest funding round
Latest funding round
$ 3.1m (over 3 years ago)
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
$ 139.9m (5 months ago)
Total funding raised
Total funding raised
$ 58.2m
Total funding raised
$ 20m
Total funding raised
N/A
Total funding raised
$ 38.4m
Total funding raised
$ 765m
For sources of this data, please see the company profileDownload Excel

View company profiles

Nemus Bioscience
HQ
Costa Mesa, US
Employees
3

Nemus Bioscience Inc. is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids.

View company
Keryx Biopharmaceuticals
HQ
New York, US
Employees
193

Keryx Biopharmaceuticals is a biopharmaceutical company focused on the development of products for the treatment of renal diseases.

View company
Reneuron Group
HQ
Surrey Research Park, GB
Employees
53↑ 20% increase

ReNeuron Group engages in R&D and the commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications.

View company
Oxford Nanopore Technologies
HQ
Oxford, GB
Employees
310↑ 1% increase

Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA and proteins.

View company